时间：2026年6月4日
Date: June 4, 2026
科伦博泰新型抗癌药SKB500震撼ASCO 2026：小细胞肺癌患者应答率高达65%
Kelun-Biotech’s Novel Cancer Drug SKB500 Stuns ASCO 2026: 65% Response Rate in Small Cell Lung Cancer Patients
摘要 :
四川科伦博泰生物医药股份有限公司在芝加哥2026年ASCO年会上展示了靶向B7-H3的新型抗体药物偶联物SKB500的首次人体临床数据（摘要#3011）。该I期剂量递增和扩展研究纳入了192名五种癌症类型的晚期实体瘤患者，数据截止日期为2026年3月31日。在推荐的12 mg/kg剂量水平，所有瘤种总体客观缓解率达42.7%，疾病控制率为83.9%。最引人注目的是，小细胞肺癌患者（n=40）取得了65%的客观缓解率、95%的疾病控制率和7.2个月的中位无进展生存期。食管鳞状细胞癌患者的缓解率为54.1%。推荐剂量下3级及以上治疗相关不良事件发生率为32.3%，以血液学毒性为主，未报告治疗相关死亡。
Summary :
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented compelling first-in-human clinical data for SKB500, a novel antibody-drug conjugate targeting B7-H3, at the 2026 ASCO Annual Meeting in Chicago (Abstract #3011). The Phase 1 dose-escalation and expansion study enrolled 192 patients with advanced solid tumors across five cancer types, with data cutoff on March 31, 2026. At the recommended 12 mg/kg dose level, the overall objective response rate reached 42.7% with a disease control rate of 83.9% across all tumor types. Most strikingly, small cell lung cancer patients (n=40) achieved a 65% objective response rate, 95% disease control rate, and median progression-free survival of 7.2 months. Esophageal squamous cell carcinoma patients showed a 54.1% response rate. Grade 3 or higher treatment-related adverse events occurred in 32.3% of patients at the recommended dose, primarily hematologic, with no treatment-related deaths reported.
入选理由 :
在小细胞肺癌——肿瘤学中最致命的诊断之一——的I期首次人体研究中取得65%的缓解率，堪称卓越。科伦博泰SKB500数据将中国药物创新推上全球最大的肿瘤学舞台（ASCO），证明中国自主研发的ADC技术能够在癌症治疗的全球前沿展开竞争。
Why Selected：
A 65% response rate in small cell lung cancer — one of oncology’s most lethal diagnoses — from a Phase 1 first-in-human study is extraordinary. Kelun-Biotech’s SKB500 data positions China’s pharmaceutical innovation on the world’s biggest oncology stage (ASCO), demonstrating that Chinese-developed ADC technology can compete at the global frontier of cancer therapeutics.
浏览量：680,000+
Views：680,000+
独立IP：225,000+
Unique Clicks ：225,000+
